- Home
- BMEZ vs GERN Comparison
BMEZ vs GERN Comparison
Compare BMEZ & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMEZ | GERN |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.9M | 753.3M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | BMEZ | GERN |
|---|---|---|
| Price | $15.24 | $1.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 391.3K | ★ 7.0M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | N/A | ★ $183,403,000.00 |
| Revenue This Year | N/A | $147.42 |
| Revenue Next Year | N/A | $39.42 |
| P/E Ratio | $30.17 | ★ N/A |
| Revenue Growth | N/A | ★ 522.13 |
| 52 Week Low | $12.93 | $1.04 |
| 52 Week High | $16.95 | $3.68 |
Technical Indicators
Market Signals| Indicator | BMEZ | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 57.62 |
| Support Level | $14.92 | $1.30 |
| Resistance Level | $15.28 | $1.37 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 51.30 | 64.58 |
Price Performance
Historical ComparisonAbout BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.